Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCC-3116 + tebentafusp
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
DCC-3116 + tebentafusp is an investigational combination therapy being evaluated for the treatment of HLA-A*02:01-positive metastatic uveal melanoma. The combination consists of **DCC-3116** (also known by the development code **DCSZ11**), a potent and selective small-molecule inhibitor of the Unc-51 like autophagy activating kinases 1 and 2 (**ULK1/2**), and **tebentafusp** (**Kimmtrak**), a first-in-class bispecific T-cell receptor (TCR) T-cell engager. DCC-3116 is designed to inhibit autophagy, a cellular stress-response mechanism that tumors utilize to survive metabolic stress and resist immune-mediated killing. Tebentafusp targets the melanocyte-associated antigen **gp100** presented by HLA-A*02:01 and redirects T cells to the tumor via a CD3-binding domain. The rationale for this combination is that inhibiting autophagy may sensitize tumor cells to T-cell mediated cytotoxicity and overcome potential resistance mechanisms to T-cell engager therapy.
- Other names
- DCSZ11 + tebentafuspDCC-3116 + tebentafusp
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD93 (CD93 antigen)PMEL (Melanocyte Protein PMEL)ULK1ULK2 (Unc-51-like kinase 2)
Beyond the preview
Go deeper on DCC-3116 + tebentafusp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCC-3116 + tebentafusp.